Driving impairment and altered ocular activity under the effects of alprazolam and alcohol: A randomized, double-blind, placebo-controlled study

被引:5
作者
Aitken, Blair [1 ]
Hayley, Amie C. [1 ,2 ]
Ford, Talitha C. [1 ,3 ]
Geier, Lauren [4 ]
Shiferaw, Brook A. [1 ,2 ,5 ]
Downey, Luke A. [1 ,2 ,6 ]
机构
[1] Swinburne Univ Technol, Ctr Human Psychopharmacol, Hawthorn, Vic, Australia
[2] Austin Hlth, Inst Breathing & Sleep IBAS, Heidelberg, Vic, Australia
[3] Deakin Univ, Cognit Neurosci Unit, Geelong, Vic, Australia
[4] Forens Sci South Australia, Adelaide, Australia
[5] Seeing Machines, Canberra, ACT 2612, Australia
[6] Swinburne Univ Technol, Ctr Mental Hlth & Brain Sci, Hawthorn, Vic 3122, Australia
基金
英国医学研究理事会;
关键词
Alcohol; Alprazolam; Driving; Gaze entropy; Ocular monitoring; Road safety; PERFORMANCE; PREVALENCE; RISK; BENZODIAZEPINES; RESPONSIBILITY; PSYCHOMOTOR; DRUGS;
D O I
10.1016/j.drugalcdep.2023.110919
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Alprazolam, also known by trade-name Xanax, is regularly detected along with alcohol in blood samples of drivers injured or killed in traffic collisions. While their co-consumption is principally legal, policy guidelines concerning fitness-to-drive are lacking and methods to index impairment are underdeveloped. Methods: In this randomized, double-blind, placebo-controlled, crossover trial, we examined whether legally permissible levels of alcohol [target 0.04% blood alcohol concentration (BAC)], alprazolam (1 mg), and their combination impacts driving performance, and whether driving impairment can be indexed by ocular activity. Participants completed a test battery consisting of a 40-minute simulated highway drive with ocular parameters assessed simultaneously, the Karolinska Sleepiness Scale, and a confidence to drive assessment following four separate treatment combinations. The predictive efficacy of ocular parameters to identify alcohol and alprazolam-related driving impairment was also examined.Results: Among 21 healthy, fully licensed drivers (37% female, mean age 28.43, SD & PLUSMN; 3.96), driving performance was significantly impacted by alprazolam, alcohol, and their combination. Linear regression models revealed that the odds of an out-of-lane event occurring increased five-fold under the influence alprazolam alone and when combined with alcohol. An increase in gaze transition entropy (GTE) demonstrated the strongest association with the odds of an out-of-lane event occurring in the same minute, with both microsleeps and fixation rate achieving moderate accuracy across treatments.Conclusions: Alprazolam and alcohol, alone and in combination, impaired select aspects of vehicle control over time. GTE, microsleeps, and fixation rate show potential as real-time indicators of driving impairment and crash risk associated with alcohol and alprazolam consumption.
引用
收藏
页数:10
相关论文
共 50 条
[11]   Randomized, Placebo-Controlled, Double-Blind Study of Ropinirole in Chronic Stroke [J].
Cramer, Steven C. ;
Dobkin, Bruce H. ;
Noser, Elizabeth A. ;
Rodriguez, Rachelle W. ;
Enney, Lori A. .
STROKE, 2009, 40 (09) :3034-3038
[12]   SIAXI Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea [J].
Jost, Wolfgang H. ;
Friedman, Andrzej ;
Michel, Olaf ;
Oehlwein, Christian ;
Slawek, Jaroslaw ;
Bogucki, Andrzej ;
Ochudlo, Stanislaw ;
Banach, Marta ;
Pagan, Fernando ;
Flatau-Baque, Birgit ;
Csikos, Janos ;
Cairney, Claire J. ;
Blitzer, Andrew .
NEUROLOGY, 2019, 92 (17) :E1982-E1991
[13]   Hepatoprotective Effects of a Proprietary Glycyrrhizin Product during Alcohol Consumption: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study [J].
Chigurupati, Harsha ;
Auddy, Biswajit ;
Biyani, M. ;
Stohs, Sidney J. .
PHYTOTHERAPY RESEARCH, 2016, 30 (12) :1943-1953
[14]   A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Naltrexone in Outpatients With Bipolar Disorder and Alcohol Dependence [J].
Brown, E. Sherwood ;
Carmody, Thomas J. ;
Schmitz, Joy M. ;
Caetano, Raul ;
Adinoff, Bryon ;
Swann, Alan C. ;
Rush, A. John .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2009, 33 (11) :1863-1869
[15]   Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study [J].
Kraglund, Kristian Lundsgaard ;
Mortensen, Janne Kaergaard ;
Johnsen, Soren Paaske ;
Andersen, Grethe ;
Grove, Erik Lerkevang .
SCIENTIFIC REPORTS, 2019, 9 (1)
[16]   Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study [J].
Stenberg, Jan-Henry ;
Terevnikov, Viatcheslav ;
Joffe, Marina ;
Tiihonen, Jari ;
Tchoukhine, Evgueni ;
Burkin, Mark ;
Joffe, Grigori .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 (04) :433-441
[17]   Tradipitant in the Treatment of Motion Sickness: A Randomized, Double-Blind, Placebo-Controlled Study [J].
Polymeropoulos, Vasilios M. ;
Czeisler, Mark E. ;
Gibson, Mary M. ;
Anderson, Austin A. ;
Miglo, Jane ;
Wang, Jingyuan ;
Xiao, Changfu ;
Polymeropoulos, Christos M. ;
Birznieks, Gunther ;
Polymeropoulos, Mihael H. .
FRONTIERS IN NEUROLOGY, 2020, 11
[18]   Pregabalin for anxiety in patients with schizophrenia - A randomized, double-blind placebo-controlled study [J].
Schjerning, Ole ;
Damkier, Per ;
Lykkegaard, Signe Engelhardt ;
Jakobsen, Klaus Damgaard ;
Nielsen, Jimmi .
SCHIZOPHRENIA RESEARCH, 2018, 195 :260-266
[19]   New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide [J].
Gunal, DI ;
Afsar, N ;
Bekiroglu, N ;
Aktan, S .
NEUROLOGICAL SCIENCES, 2000, 21 (05) :315-317
[20]   New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide [J].
D.İ Gunal ;
N. Afşar ;
N. Bekiroglu ;
S. Aktan .
Neurological Sciences, 2000, 21 :315-317